While PD-1 blockade has not been successful in MM, with clinical trials utilizing PD-1 inhibitors being suspended prematurely for increased mortality [28, 29], CD94/NKG2A-HLA-E axis represents an important immune checkpoint to study. Here, KLRC1 is linked to Miyoshi myopathy.